Effectiveness of the Standard WHO Recommended Retreatment Regimen (Category II) for Tuberculosis in Kampala, Uganda: A Prospective Cohort Study

被引:52
作者
Jones-Lopez, Edward C. [1 ,2 ,3 ]
Ayakaka, Irene [2 ]
Levin, Jonathan [4 ,5 ]
Reilly, Nancy [3 ]
Mumbowa, Francis [6 ]
Dryden-Peterson, Scott [7 ]
Nyakoojo, Grace [2 ]
Fennelly, Kevin [2 ,8 ]
Temple, Beth [4 ]
Nakubulwa, Susan [4 ]
Joloba, Moses L. [6 ]
Okwera, Alphonse [2 ,9 ]
Eisenach, Kathleen D. [10 ,11 ]
McNerney, Ruth [12 ,13 ]
Elliott, Alison M. [14 ]
Ellner, Jerrold J. [1 ,2 ]
Smith, Peter G.
Mugerwa, Roy D. [2 ,14 ]
机构
[1] Boston Univ, Sch Med, Dept Med, Sect Infect Dis,Boston Med Ctr, Boston, MA 02118 USA
[2] Makerere Univ, UMDNJ Res Collaborat, Kampala, Uganda
[3] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA
[4] MRC, Uganda Virus Res Inst, Uganda Res Unit AIDS, Entebbe, Uganda
[5] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa
[6] Makerere Univ, Dept Microbiol, Coll Hlth Sci, Kampala, Uganda
[7] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Infect Dis, Boston, MA 02115 USA
[8] Univ Florida, Dept Med, Div Mycobacteriol, SE Natl TB Ctr, Gainesville, FL USA
[9] Mulago Hosp, TB Clin, Kampala, Uganda
[10] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA
[11] Univ Arkansas Med Sci, Dept Microbiol & Immunol, Little Rock, AR 72205 USA
[12] Univ London London Sch Hyg & Trop Med, Dept Infect Dis, London WC1E 7HT, England
[13] Univ London London Sch Hyg & Trop Med, Dept Trop Dis, London WC1E 7HT, England
[14] Makerere Univ, Dept Med, Coll Hlth Sci, Kampala, Uganda
基金
英国惠康基金;
关键词
MULTIDRUG-RESISTANT TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; TREATMENT OUTCOMES; DRUG-RESISTANCE; FAILURE; MANAGEMENT; THERAPY; PROGRAM; RELAPSE; MODEL;
D O I
10.1371/journal.pmed.1000427
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Each year, 10%-20% of patients with tuberculosis (TB) in low-and middle-income countries present with previously treated TB and are empirically started on a World Health Organization (WHO)-recommended standardized retreatment regimen. The effectiveness of this retreatment regimen has not been systematically evaluated. Methods and Findings: From July 2003 to January 2007, we enrolled smear-positive, pulmonary TB patients into a prospective cohort to study treatment outcomes and mortality during and after treatment with the standardized retreatment regimen. Median time of follow-up was 21 months (interquartile range 12-33 months). A total of 29/148 (20%) HIV-uninfected and 37/140 (26%) HIV-infected patients had an unsuccessful treatment outcome. In a multiple logistic regression analysis to adjust for confounding, factors associated with an unsuccessful treatment outcome were poor adherence (adjusted odds ratio [aOR] associated with missing half or more of scheduled doses 2.39; 95% confidence interval (CI) 1.10-5.22), HIV infection (2.16; 1.01-4.61), age (aOR for 10-year increase 1.59; 1.13-2.25), and duration of TB symptoms (aOR for 1-month increase 1.12; 1.04-1.20). All patients with multidrug-resistant TB had an unsuccessful treatment outcome. HIV-infected individuals were more likely to die than HIV-uninfected individuals (p<0.0001). Multidrug-resistant TB at enrolment was the only common risk factor for death during follow-up for both HIV-infected (adjusted hazard ratio [aHR] 17.9; 6.0-53.4) and HIV-uninfected (14.7; 4.1-52.2) individuals. Other risk factors for death during follow-up among HIV-infected patients were CD4<50 cells/ml and no antiretroviral treatment (aHR 7.4, compared to patients with CD4 >= 200; 3.0-18.8) and Karnofsky score <70 (2.1; 1.1-4.1); and among HIV-uninfected patients were poor adherence (missing half or more of doses) (3.5; 1.1-10.6) and duration of TB symptoms (aHR for a 1-month increase 1.9; 1.0-3.5). Conclusions: The recommended regimen for retreatment TB in Uganda yields an unacceptable proportion of unsuccessful outcomes. There is a need to evaluate new treatment strategies in these patients.
引用
收藏
页数:10
相关论文
共 42 条
[1]  
[Anonymous], 2009, GLOB TUB CONTR SHORT
[2]  
[Anonymous], 2009, Treatment of tuberculosis guidelines
[3]  
*BECT DICK CO, BACT 460 SYST PROD P
[4]  
*BECT DICK CO, BACT MGIT 960 SYST U
[5]  
Cavalcante SC, 2007, INT J TUBERC LUNG D, V11, P544
[6]  
Churchyard GJ, 2000, INT J TUBERC LUNG D, V4, P433
[7]   Tuberculosis recurrence and mortality after successful treatment:: Impact of drug resistance [J].
Cox, Helen ;
Kebede, Yared ;
Allamuratova, Sholpan ;
Ismailov, Gabit ;
Davletmuratova, Zamira ;
Byrnes, Graham ;
Stone, Christine ;
Niemann, Stefan ;
Ruesch-Gerdes, Sabine ;
Blok, Lucie ;
Doshetov, Daribay .
PLOS MEDICINE, 2006, 3 (10) :1836-1843
[8]   Standard short-course chemotherapy for drug-resistant tuberculosis -: Treatment outcomes in 6 countries [J].
Espinal, MA ;
Kim, SJ ;
Suarez, PG ;
Kam, KM ;
Khomenko, AG ;
Migliori, GB ;
Baéz, J ;
Kochi, A ;
Dye, C ;
Raviglione, MC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (19) :2537-2545
[9]  
Espinal MA, 2003, INT J TUBERC LUNG D, V7, P607
[10]   From threat to reality - The real face of multidrug-resistant tuberculosis [J].
Espinal, Marcos ;
Raviglione, Mario C. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 178 (03) :216-217